Stinchcombe et al argued that the practice pattern for EGFR wild-type NSCLC was platinum-based chemotherapy as first-line, immunotherapy as second-line, and single-agent chemotherapy as third-line therapy; nevertheless, only a small proportion of patients were eligible for fourth-line therapy and they should be enrolled in trials.[19] The registered trials regarding anlotinib monotherapy for lung cancer were listed in Table 2. The gene discussed is EGFR; the disease is lung cancer.